| Literature DB >> 27302958 |
Moon Ho Do1, Sun Yeou Kim1,2,3.
Abstract
Methylglyoxal (MGO) is a highly reactive metabolite of glucose which is known to cause damage and induce apoptosis in endothelial cells. Endothelial cell damage is implicated in the progression of diabetes-associated complications and atherosclerosis. Hypericin, a naphthodianthrone isolated from Hypericum perforatum L. (St. John's Wort), is a potent and selective inhibitor of protein kinase C and is reported to reduce neuropathic pain. In this work, we investigated the protective effect of hypericin on MGO-induced apoptosis in human umbilical vein endothelial cells (HUVECs). Hypericin showed significant anti-apoptotic activity in MGO-treated HUVECs. Pretreatment with hypericin significantly inhibited MGO-induced changes in cell morphology, cell death, and production of intracellular reactive oxygen species. Hypericin prevented MGO-induced apoptosis in HUVECs by increasing Bcl-2 expression and decreasing Bax expression. MGO was found to activate mitogen-activated protein kinases (MAPKs). Pretreatment with hypericin strongly inhibited the activation of MAPKs, including P38, JNK, and ERK1/2. Interestingly, hypericin also inhibited the formation of AGEs. These findings suggest that hypericin may be an effective regulator of MGO-induced apoptosis. In conclusion, hypericin downregulated the formation of AGEs and ameliorated MGO-induced dysfunction in human endothelial cells.Entities:
Keywords: Advanced glycation end products; Apoptosis; HUVECs; Hypericin; Methylglyoxal
Year: 2017 PMID: 27302958 PMCID: PMC5340540 DOI: 10.4062/biomolther.2016.034
Source DB: PubMed Journal: Biomol Ther (Seoul) ISSN: 1976-9148 Impact factor: 4.634
Fig. 1.The effect of hypericin on MGO-induced cytotoxicity and oxidative stress in HUVECs. (A) The representative photographs of MGO-treated HUVECs without (−) or with (+) hypericin. (a) control; (b) 400 μM MGO; (c) MGO+0.1 μM hypericin; (d) MGO+0.5 μM hypericin; (e) MGO+1 μM hypericin; (f) MGO+aminoguanidine. (B) The cell viability of HUVECs treated with MGO and hypericin. Cell viability was analyzed by the MTT assay. The percentage of cell viability is presented as mean ± SD of three independent experiments. (C) The protective effect of hypericin on MGO-induced ROS generation. HUVECs were pretreated with hypericin for 1 h and then treated with 400 μM MGO for 2 h. ROS generation was detected by staining with the fluorescent dye DCF-DA. (a) control; (b) 400 μM MGO; (c) MGO+hypericin; (d) MGO+aminoguanidine. (D) Fluorescent intensity was measured using Image J software. (E) The effect of hypericin on Bcl-2, Bax and p53 protein expression in MGO-treated HUVECs as assessed by Western blot. Cells were incubated without (−) or with (+) hypericin for 1 h and then treated with 400 μM MGO for 24 h. Tubulin was used as an internal control. (F) The relative band intensity of Bcl-2. (G) The relative band intensity of Bax. (H) The relative band intensity of p53. Bar values are presented as the mean ± SD of three independent experiments (**p<0.01 vs. control, ***p<0.001 vs. control, ##p<0.01 and ###p<0.001 vs. 400 μM MGO treatment only).
Fig. 2.The effects of hypericin on MAPK signaling in HUVECs. Levels of the total and phosphorylated forms of MAPKs were detected by Western blot. Cells were incubated without (−) or with (+) hypericin for 1 h and then treated with 400 μM MGO for 1 h. (A) Representative Western blots of MAPKs. (B) Relative band intensity of p-JNK. (C) Relative band intensity of p-ERK. (D) Relative band intensity of p-p38. Bar values are presented as the mean ± SD of three independent experiments (***p<0.001 vs. control, #p<0.05, ##p<0.01 and ###p<0.001 vs. 400 μM MGO treatment only).
Inhibitory effect of hypericin on AGE formation
| Sample | AGEs Formation (%) |
|---|---|
| Control | 12.24 ± 0.14 |
| MGO (400 μM) | 100.00 ± 0.89[ |
| Hypericin (1 μM) | 102.67 ± 0.11 |
| Hypericin (10 μM) | 80.06 ± 0.64 |
| Aminoguanidine (1 mM) | 28.82 ± 0.21 |
The percent of AGEs formation is presented as the mean ± SD of three independent experiments.
p<0.001 vs. control and
p< 0.001 vs. 400 μM MGO treatment only.